203 related articles for article (PubMed ID: 28077684)
1. Targeting Aurora kinase A and JAK2 prevents GVHD while maintaining Treg and antitumor CTL function.
Betts BC; Veerapathran A; Pidala J; Yang H; Horna P; Walton K; Cubitt CL; Gunawan S; Lawrence HR; Lawrence NJ; Sebti SM; Anasetti C
Sci Transl Med; 2017 Jan; 9(372):. PubMed ID: 28077684
[TBL] [Abstract][Full Text] [Related]
2. Pacritinib Combined with Sirolimus and Low-Dose Tacrolimus for GVHD Prevention after Allogeneic Hematopoietic Cell Transplantation: Preclinical and Phase I Trial Results.
Pidala J; Walton K; Elmariah H; Kim J; Mishra A; Bejanyan N; Nishihori T; Khimani F; Perez L; Faramand RG; Davila ML; Nieder ML; Sagatys EM; Holtan SG; Lawrence NJ; Lawrence HR; Blazar BR; Anasetti C; Sebti SM; Betts BC
Clin Cancer Res; 2021 May; 27(10):2712-2722. PubMed ID: 33753457
[TBL] [Abstract][Full Text] [Related]
3. Pharmacologic blockade of JAK1/JAK2 reduces GvHD and preserves the graft-versus-leukemia effect.
Choi J; Cooper ML; Alahmari B; Ritchey J; Collins L; Holt M; DiPersio JF
PLoS One; 2014; 9(10):e109799. PubMed ID: 25289677
[TBL] [Abstract][Full Text] [Related]
4. Targeting JAK2 reduces GVHD and xenograft rejection through regulation of T cell differentiation.
Betts BC; Bastian D; Iamsawat S; Nguyen H; Heinrichs JL; Wu Y; Daenthanasanmak A; Veerapathran A; O'Mahony A; Walton K; Reff J; Horna P; Sagatys EM; Lee MC; Singer J; Chang YJ; Liu C; Pidala J; Anasetti C; Yu XZ
Proc Natl Acad Sci U S A; 2018 Feb; 115(7):1582-1587. PubMed ID: 29382747
[TBL] [Abstract][Full Text] [Related]
5. Stabilization of Foxp3 by Targeting JAK2 Enhances Efficacy of CD8 Induced Regulatory T Cells in the Prevention of Graft-versus-Host Disease.
Iamsawat S; Daenthanasanmak A; Voss JH; Nguyen H; Bastian D; Liu C; Yu XZ
J Immunol; 2018 Nov; 201(9):2812-2823. PubMed ID: 30242073
[TBL] [Abstract][Full Text] [Related]
6. Janus kinase-2 inhibition induces durable tolerance to alloantigen by human dendritic cell-stimulated T cells yet preserves immunity to recall antigen.
Betts BC; Abdel-Wahab O; Curran SA; St Angelo ET; Koppikar P; Heller G; Levine RL; Young JW
Blood; 2011 Nov; 118(19):5330-9. PubMed ID: 21917753
[TBL] [Abstract][Full Text] [Related]
7. Dual JAK2/Aurora kinase A inhibition prevents human skin graft rejection by allo-inactivation and ILC2-mediated tissue repair.
Walton K; Walker K; Riddle M; Koehn BH; Reff J; Sagatys EM; Linden MA; Pidala J; Kim J; Lee MC; Kiluk JV; Hui JYC; Yun SY; Xing Y; Stefanski H; Lawrence HR; Lawrence NJ; Tolar J; Anasetti C; Blazar BR; Sebti SM; Betts BC
Am J Transplant; 2022 Mar; 22(3):717-730. PubMed ID: 34668635
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of Human Dendritic Cell ER Stress Response Reduces T Cell Alloreactivity Yet Spares Donor Anti-tumor Immunity.
Betts BC; Locke FL; Sagatys EM; Pidala J; Walton K; Menges M; Reff J; Saha A; Djeu JY; Kiluk JV; Lee MC; Kim J; Kang CW; Tang CH; Frieling J; Lynch CC; List A; Rodriguez PC; Blazar BR; Conejo-Garcia JR; Del Valle JR; Hu CC; Anasetti C
Front Immunol; 2018; 9():2887. PubMed ID: 30574153
[TBL] [Abstract][Full Text] [Related]
9. Dual Aurora A and JAK2 kinase blockade effectively suppresses malignant transformation.
Yang H; Lawrence HR; Kazi A; Gevariya H; Patel R; Luo Y; Rix U; Schonbrunn E; Lawrence NJ; Sebti SM
Oncotarget; 2014 May; 5(10):2947-61. PubMed ID: 24930769
[TBL] [Abstract][Full Text] [Related]
10. Epigenetic conversion of conventional T cells into regulatory T cells by CD28 signal deprivation.
Mikami N; Kawakami R; Chen KY; Sugimoto A; Ohkura N; Sakaguchi S
Proc Natl Acad Sci U S A; 2020 Jun; 117(22):12258-12268. PubMed ID: 32414925
[TBL] [Abstract][Full Text] [Related]
11. Pharmacologic Inhibition of JAK1/JAK2 Signaling Reduces Experimental Murine Acute GVHD While Preserving GVT Effects.
Carniti C; Gimondi S; Vendramin A; Recordati C; Confalonieri D; Bermema A; Corradini P; Mariotti J
Clin Cancer Res; 2015 Aug; 21(16):3740-9. PubMed ID: 25977345
[TBL] [Abstract][Full Text] [Related]
12. Targeting of inducible costimulator (ICOS) expressed on alloreactive T cells down-regulates graft-versus-host disease (GVHD) and facilitates engraftment of allogeneic bone marrow (BM).
Taylor PA; Panoskaltsis-Mortari A; Freeman GJ; Sharpe AH; Noelle RJ; Rudensky AY; Mak TW; Serody JS; Blazar BR
Blood; 2005 Apr; 105(8):3372-80. PubMed ID: 15618467
[TBL] [Abstract][Full Text] [Related]
13. Novel JAK Inhibitors to Reduce Graft-Versus-Host Disease after Allogeneic Hematopoietic Cell Transplantation in a Preclinical Mouse Model.
Kim S; Ruminski P; Singh M; Staser K; Ashami K; Ritchey J; Lim S; DiPersio JF; Choi J
Molecules; 2024 Apr; 29(8):. PubMed ID: 38675621
[TBL] [Abstract][Full Text] [Related]
14. IFNγR signaling mediates alloreactive T-cell trafficking and GVHD.
Choi J; Ziga ED; Ritchey J; Collins L; Prior JL; Cooper ML; Piwnica-Worms D; DiPersio JF
Blood; 2012 Nov; 120(19):4093-103. PubMed ID: 22972985
[TBL] [Abstract][Full Text] [Related]
15. During acute graft versus host disease CD28 deletion in donor CD8
Uri A; Lühder F; Kerkau T; Beyersdorf N
Eur J Immunol; 2018 Dec; 48(12):2055-2067. PubMed ID: 30320878
[TBL] [Abstract][Full Text] [Related]
16. Daratumumab Prevents Experimental Xenogeneic Graft-Versus-Host Disease by Skewing Proportions of T Cell Functional Subsets and Inhibiting T Cell Activation and Migration.
Gao Y; Shan W; Gu T; Zhang J; Wu Y; Li X; Zeng X; Zhou H; Chen Z; Xiao H
Front Immunol; 2021; 12():785774. PubMed ID: 34987512
[TBL] [Abstract][Full Text] [Related]
17. In vivo maturation of allo-specific CD8 CTL and prevention of lupus-like graft-versus-host disease is critically dependent on T cell signaling through the TNF p75 receptor but not the TNF p55 receptor.
Soloviova K; Puliaiev M; Haas M; Via CS
J Immunol; 2013 May; 190(9):4562-72. PubMed ID: 23526821
[TBL] [Abstract][Full Text] [Related]
18. BET Bromodomain Inhibitors Which Permit Treg Function Enable a Combinatorial Strategy to Suppress GVHD in Pre-clinical Allogeneic HSCT.
Copsel SN; Lightbourn CO; Barreras H; Lohse I; Wolf D; Bader CS; Manov J; Kale BJ; Shah D; Brothers SP; Perez VL; Komanduri KV; Wahlestedt C; Levy RB
Front Immunol; 2018; 9():3104. PubMed ID: 30733722
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of calcineurin abrogates while inhibition of mTOR promotes regulatory T cell expansion and graft-versus-host disease protection by IL-2 in allogeneic bone marrow transplantation.
Satake A; Schmidt AM; Nomura S; Kambayashi T
PLoS One; 2014; 9(3):e92888. PubMed ID: 24658577
[TBL] [Abstract][Full Text] [Related]
20. CD28-specific antibody prevents graft-versus-host disease in mice.
Yu XZ; Bidwell SJ; Martin PJ; Anasetti C
J Immunol; 2000 May; 164(9):4564-8. PubMed ID: 10779758
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
